Impact of Intrapartum Oral Azithromycin on the Acquired Macrolide Resistome of Infants' Nasopharynx: A Randomized Controlled Trial.
Bojang, Abdoulie;
Baines, Sarah L;
Camara, Bully;
Guerillot, Romain;
Donovan, Liam;
Marqués, Raquel Sánchez;
Secka, Ousman;
D'Alessandro, Umberto;
Bottomley, Christian;
Howden, Benjamin P;
+1 more...Roca, Anna;
(2020)
Impact of Intrapartum Oral Azithromycin on the Acquired Macrolide Resistome of Infants' Nasopharynx: A Randomized Controlled Trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 71 (12).
pp. 3222-3225.
ISSN 1058-4838
DOI: https://doi.org/10.1093/cid/ciaa609
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
UNLABELLED: In a post hoc analysis of samples from an intrapartum azithromycin randomized clinical trial, we found that children whose mothers had been treated with the drug had higher prevalence of macrolide-resistance genes msr(A) and ermC at 28 days but not at 12 months. The 2 genes were positively associated in the nasopharynx. CLINICAL TRIALS REGISTRATION: NCT1800942.